Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Average Rating of “Moderate Buy” from Analysts

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) has been given a consensus rating of “Moderate Buy” by the seventeen ratings firms that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and fourteen have given a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $18.9167.

Several brokerages have commented on ORIC. Oppenheimer reiterated an “outperform” rating and set a $15.00 target price on shares of Oric Pharmaceuticals in a research report on Tuesday, February 24th. Wall Street Zen cut shares of Oric Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 9th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Oric Pharmaceuticals in a research report on Friday, May 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oric Pharmaceuticals in a research report on Tuesday, April 21st. Finally, The Goldman Sachs Group raised shares of Oric Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $15.00 price target for the company in a report on Friday, May 15th.

Hedge Funds Weigh In On Oric Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in ORIC. Federation des caisses Desjardins du Quebec grew its holdings in shares of Oric Pharmaceuticals by 100.0% in the 4th quarter. Federation des caisses Desjardins du Quebec now owns 4,000 shares of the company’s stock valued at $33,000 after buying an additional 2,000 shares during the period. Assetmark Inc. acquired a new position in shares of Oric Pharmaceuticals in the 3rd quarter valued at $37,000. Caitong International Asset Management Co. Ltd grew its holdings in shares of Oric Pharmaceuticals by 184.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 4,528 shares of the company’s stock valued at $37,000 after buying an additional 2,936 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Oric Pharmaceuticals by 26.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,732 shares of the company’s stock valued at $39,000 after buying an additional 977 shares during the period. Finally, Russell Investments Group Ltd. acquired a new position in shares of Oric Pharmaceuticals in the 3rd quarter valued at $60,000. Institutional investors and hedge funds own 95.05% of the company’s stock.

Oric Pharmaceuticals Stock Performance

Shares of Oric Pharmaceuticals stock opened at $8.49 on Friday. The firm has a fifty day moving average of $8.98 and a two-hundred day moving average of $10.06. The stock has a market capitalization of $878.88 million, a price-to-earnings ratio of -5.90 and a beta of 1.04. Oric Pharmaceuticals has a 52 week low of $7.23 and a 52 week high of $14.93.

Oric Pharmaceuticals (NASDAQ:ORIC) last issued its earnings results on Monday, May 4th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.03). As a group, research analysts forecast that Oric Pharmaceuticals will post -1.45 EPS for the current fiscal year.

Oric Pharmaceuticals Company Profile

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.